bullish
Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation
404 Views23 Apr 2020 11:23
Akesobio, a China-based biotech company, raised USD 314 million at HKD 16.18 per share. The deal has attracted strong demands from both retail...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Akeso (康方生物) Placement - Prepping for Commercialization06 Jan 2021
- Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation23 Apr 2020
- Akesobio (康方生物) IPO: Expect near Zero Allocation14 Apr 2020
- Akesobio (康方生物) Pre-IPO: Clinical Trial Updates from PHIP08 Apr 2020
x